Female CB.17 (SCID) mice (Charles River Laboratories, Wilmington, MA, USA) at 7–12 weeks of age were maintained in a pathogen-free environment and all in vivo procedures were performed in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Synta Pharmaceuticals Corp. Institutional Animal Care and Use Committee. STAR cells were cultured as described and subcutaneously implanted into SCID mice at 5 × 106 cells per animal following suspension in 50% matrigel (BD Biosciences, Oxford, UK). Mice bearing established tumours were allocated into treatment groups of seven exhibiting similar average tumour volumes (150 mm3) and dosed intravenously with vehicle (DRD; 10% dimethyl sulphoxide, 18% Cremophor RH 40, 3.6% dextrose) or ganetespib, or orally with ABT263, using the doses and schedules indicated. Ganetespib was formulated in DRD; ABT263 in PEG400/Ethanol/Phenthol as previously described.50 (link) Tumour volumes (V) were calculated by caliper measurements of the width (W), length (L) and thickness (T) of each tumour using the formula: V=0.5236(LWT). Statistical analyses between the groups at end point were conducted using two-way ANOVA with repeated measurements (GraphPad Prism).
Female cb 17 scid mice
Manufactured by Charles River Laboratories
Sourced in United States
Female CB.17 (SCID) mice are a laboratory animal model characterized by a severe combined immunodeficiency (SCID) phenotype. These mice lack functional T and B cells, making them useful for a variety of immunological and xenograft research applications.
Automatically generated - may contain errors
Lab products found in correlation
Matrigel, by BD (1 mentions)
C57bl 6, by Charles River Laboratories (1 mentions)
Female nod scid il 2rγ nsg mice, by Jackson ImmunoResearch (1 mentions)
Gamma counter, by Hewlett-Packard (1 mentions)
Winnonlin 5, by Pharsight (1 mentions)
Fibrinogen, by Merck Group (1 mentions)
Thrombin, by Merck Group (1 mentions)
Matrigel matrix, by BD (1 mentions)
7 protocols using female cb 17 scid mice
1
Subcutaneous Xenograft Tumor Model in SCID Mice
2
Xenograft Model of Lymphoma Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female CB.17 SCID mice, five to six weeks old, were obtained from Charles River Laboratories (Wilmington, MA). Upon receipt, the mice were quarantined for minimum of three days prior to study initiation. The mice showed no signs of disease or illness upon arrival or prior to study initiation. The mice were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council) and food and water were available ad libitum. OCI-LY10 tumor cells (5.0 × 106) in serum-free medium with matrigel (1:1 ratio) were injected subcutaneously into the area under the right flank of each mouse. Tumors were allowed to reach a volume of approximately 200 mm3 prior to randomization into four treatment groups (n = 9 per group) by tumor volume. Treatments were administered daily orally. A mouse was considered to have a partial regression (PR) when tumor volume was reduced by 50% or greater, complete tumor regression (CR) when no palpable tumor could be detected. AZD2014 was prepared at 3 mg/ml in 20% captisol. Ibrutinib was prepared at 2.4 mg/ml in 0.5% methyl cellulose.
3
Husbandry and Ethics Approval for Mouse Studies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female C57BL/6, male Balb/CJ‐Nude, and female CB17 SCID mice were purchased from Charles River Laboratories. The nycthemeral cycle in the housing room is 12/12‐h light/dark, the room temperature was at 22 ± 2℃ with 55 ± 10% of relative humidity. The mice were fed ad libitum with a standard diet and filtered tap water. The laboratory animal care program and the animal facility have been fully accredited by AAALAC organization. All the experimental procedures were approved by the local ethics committee of the company and were registered at the French Ministry of Higher Education and Research.
4
Xenograft Tumor Models for GIST and NSCLC
5
Xenograft Mouse and Monkey Models
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female CB17 SCID mice 9-weeks old, approximately 22 grams, were obtained from Charles River Laboratories (San Diego, CA), and female NOD/SCID/IL-2Rγ−/− (NSG) mice (8-weeks old, approximately 22–25 grams) were obtained from The Jackson Laboratory (Sacramento, CA). A study with female cynomolgus monkeys, approximately 2 to 4 years old and weighing 2–5 kg, was conducted at Covance Inc. (Madison, WI). All animal studies were performed per their Institutional Animal Care and Use Committee-approved guidelines and protocols.
6
Pharmacokinetics of 125I-Fab'-MORF1 in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female C.B-17 SCID mice (6- to 8-week-old; 18-20 g; Charles River Laboratories) were used in all following animal experiments in this paper. Mice (n = 5) were intravenously injected with 125I-labeled Fab'-MORF1 (20 μCi per mouse; 1 nmol Fab' equivalent; 58 μg). At predetermined time intervals, 10 μL blood samples were collected from tail vein, and the radioactivity of each sample was measured with a Gamma Counter (Packard). The blood pharmacokinetic parameters were analyzed using a two-compartment model with WinNonlin 5.0.1 software (Pharsight).
7
Spheroid-based Angiogenesis Assay in SCID Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female CB17 SCID mice (Charles River, Wilmington, MA, USA) were used for the spheroid-based angiogenesis assay. Spheroids consisting of HUVECs and human microvascular PCs, pre-transfected with adenoviruses in a 1:1 ratio, were generated following established protocols [20 (link)]. Spheroids were formed by culturing cells in hanging drops of ECM containing 0.24% methylcellulose (HY-125,861, MCE, China). Spheroids of HUVECs pre-transfected with adenoviruses Ad-NC, Ad-P4HA1, a combination of Ad-P4HA1 and Ad-FBP1, or a combination of Ad-P4HA1 and Ad-TET2 were generated using the same procedure. The spheroids were then harvested, washed, and centrifuged for collection. A plug mixture, consisting of Matrigel matrix (354234, BD Biosciences, USA), spheroids, fibrinogen (2 mg/mL, 341576, Sigma, USA), methylcellulose, EC basal medium, and thrombin (10602400001, Sigma, USA) was injected into the groin of the mice (500 µL total volume) following a previously reported method [21 (link)]. After 21 days, mice were euthanized, and the plugs were harvested, embedded in paraffin, and sectioned for immunofluorescent staining of CD31.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!